High-dose melphalan in patients with multiple myeloma;Intensification therapeutique par le melphalan a haute dose dans le myeloma

Bulletin du Cancer

Volumn 86, Issue 3, 1999, Pages 283-288

  Moreau, Philippe ^a   Le Bonniec, Mireille ^b   Harousseau, Jean Luc ^a  

^a HÔTEL DIEU   (France)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Autologous stem cell transplantation; Melphalan; Multiple myeloma

Indexed keywords

INTERFERON; MELPHALAN; ALKYLATING AGENT; ANTINEOPLASTIC AGENT;

AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTIPLE MYELOMA; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; DRUG RESISTANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; MULTIMODALITY CANCER THERAPY;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INJECTIONS, INTRAVENOUS; MELPHALAN; MULTIPLE MYELOMA; TRANSPLANTATION CONDITIONING;

EID: 0033085106     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma cell leukemia and myeloma. Lancet 1983; 1: 822-4.
2. Cornbleet MA, Leonard RCF, Smyth JF. High-dose alkylating agent therapy: a review of clinical experiences. Cancer Drug Delivery 1984; 3: 227-38.
3. Bergel F, Stock JA. Cytotoxic alpha aminoacids and endopeptidase. Br Emp Cancer Comp Annu 1953; 31: 6-21.
4. Alexanian R, Haut A, Kahn AU. Treatment of multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208: 1680-5.
5. Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma. An overview of published trials. J Clin Oncol 1992; 10: 334-42.
6. Shibata T. Prolonged survival in a case of multiple myeloma treated with high dose of melphalan. Rinsho Ketsueki 1973; 14: 619-25.
7. Lokhorst HM, Meuwissen OJAT, Verdonck LF, Dekker AW. High-risk multiple myeloma treated with high-dose melphalan. J Clin Oncol 1992; 10: 47-51.
8. Barlogie B, Alexanian R, Smallwood L, Cheson B, Dixon D, Dicke K, et al. Prognostic factors with high-dose melphalan for refractory multiple myeloma. Blood 1988; 72: 215-9.
9. Barlogie B, Jagannath S, Dixon D, Cheson B, Smallwood L, Hendrickson A, et al. High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma. Blood 1990; 76: 677-80.
10. Moreau P, Fière D, Bezwoda WR, Facon T, Attal M, Laporte JP, et al. Prospective randomized placebo-controlled study of granulocytemacrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma. J Clin Oncol 1997; 15: 660-6.
11. o 318.
12. Barlogie B, Hall R, Zander A. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298-301.
13. Barlogie B, Alexanian R, Dicke K, Zagars G, Spitzer G, Jagannath S, et al. High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70: 869-74.
14. Jagannath S, Barlogie B, Dicke K, Alexanian R, Zagars G, Cheson B, et al. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood 1990; 76: 1860-6.
15. Cunningham D, Paz-Ares L, Milan S, Powles R, Nicolson M, Hickish T, et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994; 12: 759-63.
16. Alexanian R, Dimopoulos M, Smith T, Delasalle K, Barlogie B, Champlin R. Limited value of myeloablative therapy for late multiple myeloma. Blood 1994; 83: 512-6.
17. Vesole DH, Barlogie B, Jagannath S, Cheson B, Tricot G, Alexanian R, et al. High dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood 1994; 84: 950-6.
18. Gore ME, Viner C, Meldrum M, Bell J, Milan S, Zuiable A, et al. Intensive treatment for multiple myeloma and criteria for complete remission. Lancet 1989; 2: 879-81.
19. Attal M, Huguet F, Schlaifer D, Payen C, Laroche M, Fournie B, et al. Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992; 79: 1130-6.
20. Fermand JP, Chevret S, Ravaud P, Divine M, Leblond V, Dreyfus F, et al. High dose chemoradiotherapy and autologous blood stem cell transplantation in multiple transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood 1993; 82: 2005-9.
21. Harousseau JL, Attal M, Divine M, Marit G, Leblond V, Stoppa AM, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the french registry on autologous transplantation in multiple myeloma. Blood 1995; 85: 3077-85.
22. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet G, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-7.
23. Tricot G, Barlogie B, Jagannath S, Bracy D, Mattox S, Vesole DH, et al. Poor prognosis in multiple myeloma is associated with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 1995; 86: 4250-6.
24. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131-6.
25. Barlogie B, Jagannath S, Vesole DH, Naucke S, Cheson B, Mattox S, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789-93.
26. Attal M. American Society of Hematology 1998.
27. Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol 1995; 13: 1786-99.
28. 2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity. Br J Haematol 1996; 95: 527-30.
29. 2 melphalan followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant (soumis).
30. Moreau P. American Society of Hematology, 1998.
31. Prince HM, Imrie K, Sutherland DR, Keating A, Meharchand J, Crump RM, et al. Peripheral blood progenitor cell collections in multiple myeloma: predictors of management of inadequate collection. Br J Haematol 1996; 93: 142-5.
32. Tricot G, Jagannath S, Desikan KR, Siegel D, Munshi N, Olson E, et al. Superior mobilization of peripheral blood progenitor cell with r-metHu SCF and re-metHuG-CSF in heavily pretreated multiple myeloma patients. Blood 1996; 88 (suppl. 1): 388a.
33. Marit G, Thiessard F, Faberes C, Cony-Makhoul P, Boiron JM, Bernard P, et al. Factors affecting both peripheral blood progenitor cell mobilization and hemopotieic recovery following autologous blood progenitor cell transplantation in multiple myeloma patients: a monocentric study. Leukemia 1998; 12: 1447-56.
34. Goldschmidt H, Hegenbart U, Wallmeier M, Hohaus S, Haas R. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte-colony stimulating factor. Br J Haematol 1997; 98: 736-44.
35. Tarella C, Boccadoro M, Omede P, Bondesan P, Caracciolo D, Frieri R, et al. Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma. Bone Marrow Transplant 1993; 11: 271-7.
36. Harousseau JL, Attal M, Divine M, Milpied N, Marit G, Leblond V, et al. Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction in multiple myeloma. Bone Marrow Transplant 1995; 15: 963-9.
37. Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C, et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma. Br J Haematol 1998; 102: 495-502.
38. Palombo A, Pileri A, Triolo S, Omede P, Bruno B, Ciravegna G, et al. Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients. Bone Marrow Transplant 1997; 19: 23-9.
39. Tricot G, Jagannath S, Vesole DH, Crowley J, Barlogie B. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant 1995; 16: 7-11.
40. Colombat P, Milpied N, Laporte JP, Casassus P, Linassier C, Harousseau JL. Three courses of high-dose therapy in multiple myeloma. Cancer 1994; 74: 2930-6.
41. Mehta J, Tricot G, Jagannath S, Ayers D, Singhal S, Siegel D, et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft. Bone Marrow Transplant 1998; 21: 887-92.